Veru Inc. (NASDAQ: VERU) reported its financial results for the quarter ended March 31, 2020, on Wednesday before the market opens. The company posted a narrower loss for Q2 as the substantial growth in prescription sales of FC2 drove the top-line higher.
On Tuesday, Veru received FDA permission to initiate a phase 2 clinical trial to assess the efficacy of VERU-111 in combating COVID-19, the global pandemic disease caused by the novel coronavirus SARS-CoV-2. Veru has initiated the study and expects the first patient to be dosed within 2 weeks.
The company believes that VERU-111, a microtubule depolymerization agent that has broad antiviral activity, could be effective against the SARS CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to cause infection.
Past Performance
Most Popular
Netflix (NFLX) Q3 earnings beat Street View; subscribers grow 14%
Netflix, Inc. (NASDAQ: NFLX) on Thursday reported higher revenues and profit for the third quarter, as the streaming giant's subscriber base continued to expand. Both earnings and the top line
Southwest Airlines (LUV) set to report Q3 2024 earnings results next week, what to expect
Shares of Southwest Airlines Co. (NYSE: LUV) were down over 2% on Thursday. The stock has gained 9% over the past three months. The airline is slated to report its
Infographic: Key highlights from Infosys’ (INFY) Q2 FY25 earnings results
Infosys (NYSE: INFY) reported its second quarter 2025 earnings results today. Reported revenues were $4.89 billion, up 3.7% year-over-year. Revenues grew 3.3% YoY in constant currency. Net profit was $778
